Horizon Therapeutics (HZNP) | Stock Overview & Key Data
Horizon Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $39.49 on July 20, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Horizon Therapeutics
HZNP
|
26.63B Large-cap | N/A | N/A | N/A | N/A | N/A | -6.82% | 74.04% | 9.84% | 176.66% | 176.66% | 176.66% |
|
Eli Lilly and
LLY
|
821.31B Mega-cap | -1.72% | 12.38% | 14.18% | 6.32% | 4.53% | 38.28% | 153.07% | 418.42% | 1,433.98% | 2,935.09% | 1,988.48% |
| 555.84B Mega-cap | 1.51% | 3.95% | -3.10% | 10.03% | 13.65% | 53.32% | 46.67% | 48.70% | 108.58% | 263.36% | 290.52% | |
|
Merck & Co
MRK
|
283.10B Mega-cap | -3.87% | 3.16% | -0.46% | 14.60% | 7.94% | 45.70% | 8.90% | 55.40% | 123.23% | 252.74% | 262.85% |
|
Amgen
AMGN
|
187.93B Large-cap | 1.39% | 7.42% | -4.29% | 7.75% | 6.99% | 20.32% | 54.66% | 48.82% | 137.40% | 512.31% | 431.58% |
|
Pfizer
PFE
|
153.59B Large-cap | 1.48% | 2.65% | -2.29% | -1.63% | 3.26% | 6.81% | -34.57% | -32.47% | -19.28% | 36.37% | 17.90% |
Ownership & Short Interest
Calculate Your Horizon Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Horizon Therapeutics stock price in Jul 2016 was $18.86, A $1,000.00 lump sum investment in Horizon Therapeutics made 8 years ago would be worth approximately $6,166.49 today, representing a exceptional return of 516.65%. This translates to an annualized return (CAGR) of 22.61%.
8 Years 11 Months Investment Scenario (Jul 2016 - Jun 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is HZNP's 52-week high and low?
- In the last 52 weeks, Horizon Therapeutics reached a high of $116.34 (on February 6, 2025) and a low of $116.30 (on February 6, 2025).
- What is the market cap and P/E ratio for HZNP?
- Curious about Horizon Therapeutics's size and valuation? Its market capitalization stands at 26.63B. When it comes to valuation, the P/E ratio (trailing twelve months) is 61.86, and the forward P/E (looking ahead) is 20.55.
- Does HZNP pay dividends? If so, what's the yield?
- As for dividends, Horizon Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Horizon Therapeutics's main competitors or similar companies to consider before investing?
When looking at Horizon Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY821.31B Healthcare Drug Manufacturers - General 38.28% 153.07% Johnson & Johnson
JNJ555.84B Healthcare Drug Manufacturers - General 53.32% 46.67% Merck & Co
MRK283.10B Healthcare Drug Manufacturers - General 45.70% 8.90% Amgen
AMGN187.93B Healthcare Drug Manufacturers - General 20.32% 54.66% Pfizer
PFE153.59B Healthcare Drug Manufacturers - General 6.81% -34.57% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Horizon Therapeutics Plc? (e.g., ROE, Debt/Equity)
- To get a sense of Horizon Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.28%, the Debt to Equity ratio from the most recent quarter is 0.48, and its Gross Profit Margin stands at 76.72%.
- What is the recent revenue and earnings growth for HZNP?
- Looking at Horizon Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 13.57%, and quarterly earnings saw a YoY growth of N/A.
- How much of HZNP stock is held by insiders and institutions?
- Wondering who owns Horizon Therapeutics stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.